Anti-FCRN antibodies and methods of use thereof

Abstract

The present disclosure provides, among other things, antibodies and antibody fragments that bind to neonatal Fc receptor (FcRn). Pharmaceutical compositions comprising the engineered proteins disclosed herein and methods of using the same are also provided.

Description

Attorney Docket No. VRD-020W01ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 737,467 filed December 20, 2024, the content of which is hereby incorporated by reference in its entirety.BACKGROUND

[0002] The neonatal Fc receptor (FcRn) is an MHC class I— like molecule that is widely distributed in mammalian organs, tissues, and cells. FcRn is critical to maintaining immunoglobulin G (IgG) and albumin levels through rescuing these molecules from lysosomal degradation. Inhibition of IgG binding to FcRn accelerates destruction of IgG via lysosomal degradation. Using this targeted mechanism to reduce tissue and serum concentrations of IgG has the potential to provide significant therapeutic benefit for patients with both monomeric and IC (immune complex)-IgG autoantibody-mediated diseases.SUMMARY OF THE INVENTION

[0003] The present invention provides, among other things, an antibody or antigen binding fragment that binds to neonatal Fc receptor (FcRn) with high affinity. The anti -FcRn antibodies of the present invention (1) inhibit IgG binding to FcRn with subnanomolar potency, (2) do not inhibit albumin binding and recycling, and (3) show deep and sustained IgG reduction in vivo.

[0004] In one aspect, the present invention provides, among other things an antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn). In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 2, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 14. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising anAttorney Docket No. VRD-020W01 amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26.

[0005] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 2, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 14. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 23, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27.

[0006] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 8, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 19, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 24, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26.

[0007] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 9, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 28.

[0008] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 2, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 14. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27.

[0009] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 8, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27.

[0010] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 8, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26.[OH] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 9, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27.

[0012] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27.

[0013] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 9, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 29.

[0014] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26.

[0015] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 8, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27.

[0016] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 5, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 10, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 16. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 20, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 25, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 30.

[0017] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 5, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 10, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 16. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 21, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 25, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 30.

[0018] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 11, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26.

[0019] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 5, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 10, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 17. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 20, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 25, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 30.

[0020] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 12, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26.

[0021] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 6, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 13, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26.

[0022] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 9, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 19, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 24, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26.

[0023] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 31, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 45. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55.

[0024] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 31, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 45. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 52, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56.

[0025] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 32, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 49, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 53, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55.

[0026] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 33, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 57.

[0027] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 31, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 45. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56.

[0028] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 33, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56.

[0029] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 32, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55.

[0030] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 34, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56.

[0031] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 35, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56.

[0032] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 34, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 58.

[0033] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 36, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55.

[0034] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 37, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56.

[0035] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 38, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 43, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 47. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 50, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 54, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 59.

[0036] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 35, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55.

[0037] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 38, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 43, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 47. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 50, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 54, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 59.

[0038] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 33, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55.

[0039] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 39, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 44, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55.

[0040] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 32, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 49, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 53, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55.

[0041] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 60, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 74. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84.

[0042] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 60, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 74. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 52, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85.

[0043] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 61, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 82, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 53, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84.

[0044] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 62, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 71, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 86.

[0045] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 60, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 74. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85.

[0046] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 62, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85.

[0047] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 61, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84.

[0048] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 63, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 71, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 76. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85.

[0049] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 64, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 77. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85.

[0050] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 63, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 71, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 76. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 87.

[0051] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 65, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84.

[0052] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 66, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 78. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85.

[0053] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 67, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 72, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 79. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 83, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 54, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 88.

[0054] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 64, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 71, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 77. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84.

[0055] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 67, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 72, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 80. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 83, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 54, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 88.

[0056] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 62, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 77. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84.

[0057] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 68, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 73, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84.

[0058] In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 61, (ii) a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 71, and (iii) a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence that is identicalAttorney Docket No. VRD-020W01 to or differs by no more than 2 amino acids from SEQ ID NO: 82, (ii) a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 53, and (iii) a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84.

[0059] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 7, a HCDR3 of SEQ ID NO: 14, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 7, a HCDR3 of SEQ ID NO: 14, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 23, and a LCDR3 of SEQ ID NO: 27. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 8, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 19, a LCDR2 of SEQ ID NO: 24, and a LCDR3 of SEQ ID NO: 26. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 28.

[0060] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 7 a HCDR3 of SEQ ID NO: 14, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 8, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 8, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27.

[0061] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 7, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 ofAttorney Docket No. VRD-020W01SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 29; a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 7, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 8, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27.

[0062] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 5, a HCDR2 of SEQ ID NO: 10, a HCDR3 of SEQ ID NO: 16, a LCDR1 of SEQ ID NO: 20, a LCDR2 of SEQ ID NO: 25, and a LCDR3 of SEQ ID NO: 30. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 5, a HCDR2 of SEQ ID NO: 10, a HCDR3 of SEQ ID NO: 16, a LCDR1 of SEQ ID NO: 21, a LCDR2 of SEQ ID NO: 25, and a LCDR3 of SEQ ID NO: 30. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 11, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 5, a HCDR2 of SEQ ID NO: 10, a HCDR3 of SEQ ID NO: 17, a LCDR1 of SEQ ID NO: 20, a LCDR2 of SEQ ID NO: 25, and a LCDR3 of SEQ ID NO: 30.

[0063] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 12, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 6, a HCDR2 of SEQ ID NO: 13, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 19, a LCDR2 of SEQ ID NO: 24, and a LCDR3 of SEQ ID NO: 26.

[0064] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 31, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 45, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 31, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 45, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 52, and a LCDR3 of SEQ ID NO: 56 In someAttorney Docket No. VRD-020W01 embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 32, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 49, a LCDR2 of SEQ ID NO: 53, and a LCDR3 of SEQ ID NO: 55. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 33, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48 a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 57.

[0065] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 31, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 45, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 33, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 32, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55 In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 34, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56.

[0066] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 35, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 34, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 58. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 36, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 37, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56.

[0067] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 38, a HCDR2 of SEQ ID NO: 43, a HCDR3 of SEQ ID NO: 47, a LCDR1 of SEQ ID NO: 50, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 59.Attorney Docket No. VRD-020W01In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 38, a HCDR2 of SEQ ID NO: 43, a HCDR3 of SEQ ID NO: 47, a LCDR1 of SEQ ID NO: 50, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 59 In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 35, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 38, a HCDR2 of SEQ ID NO: 43, a HCDR3 of SEQ ID NO: 47, a LCDR1 of SEQ ID NO: 50, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 59.

[0068] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 33, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55 In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 39, a HCDR2 of SEQ ID NO: 44, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 32, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 49, a LCDR2 of SEQ ID NO: 53, and a LCDR3 of SEQ ID NO: 55.

[0069] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 60, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 74, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84 In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 60, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 74, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 52, and a LCDR3 of SEQ ID NO: 85. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 61, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 82, a LCDR2 of SEQ ID NO: 53, and a LCDR3 of SEQ ID NO: 84 In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 62, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 86.

[0070] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 60, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 74, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85.Attorney Docket No. VRD-020W01In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 62, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 61, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 63, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 76, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85.

[0071] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 64, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 77, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 63, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 76, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 87. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 65, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 66, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 78, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85.

[0072] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 67, a HCDR2 of SEQ ID NO: 72, a HCDR3 of SEQ ID NO: 79, a LCDR1 of SEQ ID NO: 83, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 88. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 67, a HCDR2 of SEQ ID NO: 72, a HCDR3 of SEQ ID NO: 79, a LCDR1 of SEQ ID NO: 83, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 88. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 64, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 77, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 67, a HCDR2 of SEQ ID NO: 72, a HCDR3 of SEQ ID NO: 80, a LCDR1 of SEQ ID NO: 83, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 88.Attorney Docket No. VRD-020W01

[0073] In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 62, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 77, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 68, a HCDR2 of SEQ ID NO: 73, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84. In some embodiments, the antibody or antigen binding fragment thereof comprises a HCDR1 of SEQ ID NO: 61, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 82, a LCDR2 of SEQ ID NO: 53, and a LCDR3 of SEQ ID NO: 84.

[0074] In some embodiments, the antibody or antigen binding fragment thereof comprises a heavy chain variable region (VH) comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence according to any one of SEQ ID NOs: 89-107.

[0075] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 96%Attorney Docket No. VRD-020W01 identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 89.

[0076] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 90.

[0077] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 91.

[0078] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%Attorney Docket No. VRD-020W01 identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 92.

[0079] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 93.

[0080] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acidAttorney Docket No. VRD-020W01 sequence at least 97% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 94.

[0081] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 95.

[0082] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 96.

[0083] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acidAttorney Docket No. VRD-020W01 sequence at least 80% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 97.

[0084] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 98.

[0085] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 99. In some embodiments, the VH comprisesAttorney Docket No. VRD-020W01 an amino acid sequence at least 98% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 99.

[0086] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 100.

[0087] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 101.

[0088] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%Attorney Docket No. VRD-020W01 identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 102.

[0089] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 103.

[0090] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 95%Attorney Docket No. VRD-020W01 identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 104.

[0091] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 105.

[0092] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 99%Attorney Docket No. VRD-020W01 identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 106.

[0093] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 107.

[0094] In some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (VL) comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof antibody comprises a light chain variable region (VL) comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to any one of SEQ ID NOs: 108- 126. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence according to any one of SEQ ID NOs: 108-126.Attorney Docket No. VRD-020W01

[0095] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 108.

[0096] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 109.

[0097] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 110. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 110.

[0098] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 111.

[0099] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 112. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 112.

[0100] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 113.

[0101] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 114.Attorney Docket No. VRD-020W01

[0102] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 115.

[0103] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 116.

[0104] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 117. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 117.

[0105] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 118.

[0106] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 119. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 119.

[0107] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 120.

[0108] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 121.Attorney Docket No. VRD-020W01

[0109] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 122.

[0110] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 123.[oni] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 124. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 124.

[0112] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 125.

[0113] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 126. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 126.

[0114] In some embodiments, the antibody or antigen binding fragment thereof comprises a Fab, a single chain Fv (scFv), a single domain antibody (VHH), one or more CDRs, a variable heavy chain (VH), a variable light chain (VL), a Fab-like bispecific antibody (bsFab), a single-domain antibody-linked Fab (s-Fab), an antibody, or a combination thereof.

[0115] In some embodiments, the antibody or antigen binding fragment thereof further comprises an Fc region. In some embodiments, the Fc region is derived from an IgGl Fc region. In some embodiments, the Fc region is derived from an IgG2 Fc region. In some embodiments, the Fc region is derived from an IgG3 Fc region. In some embodiments, the Fc region is derived from an IgG4 Fc region.

[0116] In some embodiments, the antibody or antigen binding fragment thereof comprises a heavy chain constant region (CH) comprising an amino acid sequence of SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 60% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 70% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 127.

[0117] In some embodiments, the antibody or antigen binding fragment thereof comprises a light chain constant region (CL) comprising an amino acid sequence of SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 60% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at leastAttorney Docket No. VRD-020W0170% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 128.

[0118] In some embodiments, the antibody or antigen binding fragment thereof comprises a light chain constant region (CL) comprising an amino acid sequence of SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 60% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 70% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 129.

[0119] In some embodiments, the Fc region further comprises one or more modifications. In some embodiments, the Fc region is not modified.

[0120] In some embodiments, the Fc region further comprises “knob-in-to-hole” mutations. In some embodiments, the Fc region comprises one or more amino acid substitutions selected from M252Y, S254T, T256E, M428L, H433K, N434Y, or N434F, numbered according to the EU index. In some embodiments, the Fc region comprises amino acid substitutions M252Y, S254T, T256E, H433K, and N434F; M252Y, S254T, T256E, M428L, H433K, and N434F; or M252Y, S254T, T256E, H433K, and N434Y, numbered according to the EU index. In some embodiments, the Fc region comprises amino acidAttorney Docket No. VRD-020W01 substitutions M252Y, S254T, T256E, H433K, and N434F, numbered according to the EU index. In some embodiments, the Fc region comprises amino acid substitutions M252Y, S254T, T256E, M428L, H433K, and N434F, numbered according to the EU index. In some embodiments, the Fc region comprises amino acid substitutions M252Y, S254T, T256E, H433K, and N434Y, numbered according to the EU index.

[0121] In some embodiments, the antibody or antigen binding fragment thereof is monovalent. In some embodiments, the antibody or antigen binding fragment thereof is bivalent.

[0122] In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'8M, IxlO'9M, IxlO'10M, IxlO'11M, or IxlO'12M at pH 6.0 as measured by surface plasmon resonance (SPR). In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'8M at pH 6.0 as measured by SPR. In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'9M at pH 6.0 as measured by SPR. In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'10M at pH 6.0 as measured by SPR. In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'11M at pH 6.0 as measured by SPR. In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'12M at pH 6.0 as measured by SPR.

[0123] In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'8M, IxlO'9M, IxlO'10M, IxlO'11M, or IxlO'12M at pH 7.4 as measured by SPR. In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'8M at pH 7.4 as measured by SPR. In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'9M at pH 7.4 as measured by SPR. In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'10M at pH 7.4 as measured by SPR. In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'11M at pH 7.4 as measured by SPR. In some embodiments, the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'12M at pH 7.4 as measured by SPR.Attorney Docket No. VRD-020W01

[0124] In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 10, 9, 8, 7, 6, 5, 4, 3, 2.5, 2, 1.5, or 1. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 10. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 9. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 8. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 7. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 6. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 5. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 4. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 3. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 2.5. In some embodiments, the ratio of the KD at pH7.4 to the KD at pH 6.0, as measured by SPR, is less than 2. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 1.5. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 1.

[0125] In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 10. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 9. In some embodiments, the ratio of the KD at pH7.4 to the KD at pH 6.0, as measured by SPR, is about 8. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 7. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 6. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 5. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 4. In some embodiments, the ratio of the KD at pH7.4 to the KD at pH 6.0, as measured by SPR, is about 3. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 2.5. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 2. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 1.5. In some embodiments, the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is about 1.Attorney Docket No. VRD-020W01

[0126] In some embodiments, the antibody or antigen binding fragment thereof blocks IgGs from binding to FcRn. In some embodiments, the antibody or antigen binding fragment thereof blocks or reduces naturally occurring recycling of IgGs. In some embodiments, the antibody or antigen binding fragment thereof results in increased catabolism of the IgGs. In some embodiments, the IgGs comprise pathogenic autoantibodies.

[0127] In one aspect, the present invention provides, among other things, an antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn) comprising a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 19, a LCDR2 of SEQ ID NO: 24, and a LCDR3 of SEQ ID NO: 26.

[0128] In one aspect, the present invention provides, among other things, an antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn) comprising a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 107 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 126.

[0129] In one aspect, the present invention provides, among other things, an antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn) comprising (a) a heavy chain comprising a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 107 and a heavy chain constant region (CH) comprising an amino acid sequence of SEQ ID NO: 127; and (b) a light chain comprising a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 126 and a light chain constant region (CL) comprising an amino acid sequence of SEQ ID NO: 128

[0130] In one aspect, the present invention provides, among other things, a nucleic acid encoding the antibody or antigen binding fragment thereof described herein.

[0131] In one aspect, the present invention provides, among other things, a vector comprising the nucleic acid encoding an antibody or an antigen binding fragment thereof.

[0132] In one aspect, the present invention provides, among other things, a host cell comprising the nucleic acid or the vector described herein.

[0133] In one aspect, the present invention provides, among other things, a pharmaceutical composition comprising any one of the antibody or antigen binding fragment thereof, the nucleic acid, the vector, or the host cell described herein, and a pharmaceutically acceptable carrier.

[0134] In some embodiments, the pharmaceutical composition comprises the antibody or antigen binding fragment thereof and a pharmaceutically acceptable carrier. In someAttorney Docket No. VRD-020W01 embodiments, the pharmaceutical composition comprises the nucleic acid and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises the vector and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises the host cell and a pharmaceutically acceptable carrier.

[0135] In one aspect, the present invention provides, among other things, a method of treating a disease or disorder in a patient in need thereof, the method comprising administering to the patient an effective amount of the antibody or antigen binding fragment thereof, or the pharmaceutical composition described herein. In some embodiments, a method of treating a disease or disorder in a patient in need thereof, the method comprising administering to the patient an effective amount of the antibody or antigen binding fragment thereof. In some embodiments, a method of treating a disease or disorder in a patient in need thereof, the method comprising administering to the patient an effective amount of the pharmaceutical composition.

[0136] In some embodiments, the disease is an autoimmune disease.

[0137] In some embodiments, the disease or disorder is generalized myasthenia gravis(gMG), chronic inflammatory demyelinating polyneuropathy, myositis, autoimmune encephalitis, myelin oligodendrocyte glycoprotein antibody disorders (MOG-antibody disorder), membranous nephropathy, lupus nephritis, thyroid eye disease, warm autoimmune hemolytic anemia, hemolytic disease of the fetus and newborn, idiopathic thrombocytopenic purpura, primary Sjogren’s Syndrome, systemic lupus erythematosus, rheumatoid arthritis, bullous pemphigoid, pemphigus foliaceus, pemphigus vulgaris, or cutaneous lupus erythematosus. In some embodiments, the disease or disorder is generalized myasthenia gravis (gMG). In some embodiments, the disease or disorder is chronic inflammatory demyelinating polyneuropathy. In some embodiments, the disease or disorder is myositis. In some embodiments, the disease is autoimmune encephalitis. In some embodiments, the disease or disorder is myelin oligodendrocyte glycoprotein antibody disorders (MOG- antibody disorder). In some embodiments, the disease or disorder is membranous nephropathy. In some embodiments, the disease or disorder is lupus nephritis. In some disorders, the disease is thyroid eye disease. In some embodiments, the disease or disorder is warm autoimmune hemolytic anemia. In some embodiments, the disease or disorder is hemolytic disease of the fetus and newborn. In some embodiments, the disease or disorder is idiopathic thrombocytopenic purpura. In some embodiments, the disease or disorder isAttorney Docket No. VRD-020W01Sjogren’s Syndrome. In some embodiments, the disease or disorder is systemic lupus erythematosus. In some embodiments, the disease or disorder is rheumatoid arthritis. In some embodiments, the disease or disorder is bullous pemphigoid. In some embodiments, the disease or disorder is pemphigus foliaceus. In some embodiments, the disease or disorder is pemphigus vulgaris. In some embodiments, the disease or disorder is cutaneous lupus erythematosus.

[0138] In one aspect, the present invention provides, among other things, a method for treating a pathology associated with elevated levels of an IgG in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the antibody or antigen binding fragment thereof, or the pharmaceutical composition described herein. In some embodiments, a method for treating a pathology associated with elevated levels of an IgG in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the antibody or antigen binding fragment thereof. In some embodiments, a method for treating a pathology associated with elevated levels of an IgG in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition.

[0139] In one aspect, the present invention provides, among other things, a method of reducing biological activity of an IgG in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the antibody or antigen binding fragment thereof, or the pharmaceutical composition described herein. In some embodiments, a method of reducing biological activity of an IgG in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the antibody or antigen binding fragment thereof. In some embodiments, a method of reducing biological activity of an IgG in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition.

[0140] In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 60%, to less than 50%, to less than 40%, to less than 35%, or to less than 30% relative to a baseline for at least 5 days, at least 7 days, at least 10 days, at least 15 days, or at least 20 days post-administration. In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 60% relative to a baseline for at least 5 days, at least 7 days, at least 10 days, at least 15 days, or at least 20 days post-administration. In someAttorney Docket No. VRD-020W01 embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 50% relative to a baseline for at least 5 days, at least 7 days, at least 10 days, at least 15 days, or at least 20 days post-administration. In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 40% relative to a baseline for at least 5 days, at least 7 days, at least 10 days, at least 15 days, or at least 20 days post-administration. In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 35% relative to a baseline for at least 5 days, at least 7 days, at least 10 days, at least 15 days, or at least 20 days post-administration. In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 30% relative to a baseline for at least 5 days, at least 7 days, at least 10 days, at least 15 days, or at least 20 days post-administration.

[0141] In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 60%, to less than 50%, to less than 40%, to less than 35%, or to less than 30% relative to a baseline for at least 5 days postadministration. In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 60%, to less than 50%, to less than 40%, to less than 35%, or to less than 30% relative to a baseline for at least 7 days postadministration. In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 60%, to less than 50%, to less than 40%, to less than 35%, or to less than 30% relative to a baseline for at least 10 days postadministration. In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 60%, to less than 50%, to less than 40%, to less than 35%, or to less than 30% relative to a baseline for at least 15 days postadministration. In some embodiments, administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 60%, to less than 50%, to less than 40%, to less than 35%, or to less than 30% relative to a baseline for at least 20 days postadministration.

[0142] In some embodiments, the baseline is the IgG level in the patient prior to administration of the antibody or antigen binding fragment thereof. In some embodiments, the baseline is the IgG level in a comparable patient without the administration of the antibody or antigen binding fragment thereof.Attorney Docket No. VRD-020W01BRIEF DESCRIPTION OF THE DRAWINGS

[0143] The drawings are for illustration purposes only, and are not meant to be limiting.

[0144] FIG. 1 shows exemplary graphs demonstrating the serum concentration of exemplary anti-FcRn antibodies and the IgG reduction in cynomolgus monkeys after administration of exemplary anti-FcRn antibodies.

[0145] FIG. 2 is an exemplary graph visualizing the serum albumin concentration in cynomolgus monkeys after administration of exemplary anti-FcRn antibodies.

[0146] FIG. 3 is an exemplary graph showing the serum concentrations of exemplary anti- FcRn antibodies in cynomolgus monkeys after repeated administration of the exemplary anti- FcRn antibodies.

[0147] FIG. 4 is an exemplary graph showing the mean IgG concentration in cynomolgus monkeys after repeated administration of exemplary anti-FcRn antibodies.

[0148] FIG. 5 is an exemplary graph showing the mean percent change from baseline in IgM concentrations in cynomolgus monkeys after repeated administration of exemplary anti- FcRn antibodies.

[0149] FIG. 6 is an exemplary graph showing the mean percent change from baseline in serum albumin concentrations in cynomolgus monkeys after repeated administration of exemplary anti-FcRn antibodies.

[0150] FIG. 7 is an exemplary graph showing the mean percent change from baseline in low-density lipoprotein (LDL) concentrations in cynomolgus monkeys after repeated administration of exemplary anti-FcRn antibodies.DEFINITIONS

[0151] In order for the present disclosure to be more readily understood, certain terms are first defined below. Additional definitions for the following terms and other terms are set forth throughout the specification.

[0152] Any numerical values used in this application are meant to cover any variations within the standard deviation or normal fluctuations appreciated by one of ordinary skill in the relevant art.

[0153] Antibody. As used herein, the term “antibody” refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that binds (immunoreacts with) an antigen. ByAttorney Docket No. VRD-020W01“binds” or “immunoreacts with” is meant that the antibody reacts with one or more antigenic determinants of the desired. Antibodies include antibody fragments. Antibodies also include, but are not limited to, polyclonal, monoclonal, chimeric domain antibody, single chain, Fab, Fab’, F(ab’)2 fragments, scFvs, single-domain antibodies (sdAb). An antibody may be a whole antibody, or immunoglobulin, or an antibody fragment.

[0154] CDRs'. As used herein, the term “CDR” refers to complementarity determining regions of an antibody or antigen binding fragment thereof. The CDRs are three flexible loops within a variable domain of an antibody that fold into specific structures in order to target and / or bind specific antigens. In some embodiments, the sdAbs described herein comprise 3 CDRs: a CDR1, a CDR2, and a CDR3. In some embodiments, the CDR sequences are determined by Kabat, IMGT, Chothia, or North conventions known in the art.

[0155] Knob-in-to-hole mutations'. As used herein, the term “knob-in-to-hole mutations”, “knob mutations”, and “hole mutations” refer to mutations made to promote associations of the Fc regions to an Fc domain. In some embodiments, one or more “knob mutations” are made in a first Fc region by introducing one or more bulky amino acids, and “hole mutations” are made in a second Fc region by introducing one or more smaller amino acids in corresponding positions.

[0156] Fc region'. As used herein, the term “Fc region” refers to a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In some embodiments, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, or from Asp221, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. In some embodiments, the Fc region is also referred to as an Fc domain, Fc polypeptide, or Fc dimer. In some embodiments, the Fc region comprises the CH2 and CH3 domains of an IgG. In some embodiments, the Fc region comprises the hinge, CH2, and CH3 domains of an IgG. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.

[0157] KD'. AS used herein, the term “KD”, as used herein, refers to the dissociation constant of a particular antibody-antigen interaction as is known in the art, and would applyAttorney Docket No. VRD-020W01 as a parameter of the binding affinity of a targeting moiety to its cognate ligand for the subject compositions.

[0158] sdAb'. As used herein, the term “sdAb” refers to a single domain antibody. Other terms for sdAb include, but are not limited to, domain antibody, VHH, VNAR, or nanobody. An sdAb is a kind of antibody fragment comprising a single monomeric variable antibody domain comprising a CDR1, CDR2, and CDR3. In some embodiments, the sdAb does not comprise a light chain, a constant domain, or an Fc region.

[0159] Variable domain: As used herein, the terms “variable domain” and “variable region” are used interchangeably and refer to the portions of the antibody or immunoglobulin domains that exhibit variability in their sequence and that are involved in determining the specificity and binding affinity of a particular antibody. A variable domain comprises three “hypervariable regions” or “complementarity determining regions” (CDRs) and four “framework” regions (FRM or FR) that provide a scaffold for the CDRs in three-dimensional space to form an antigen-binding surface. In some embodiments, the variable domain is a light chain variable domain. In some embodiments, the variable domain is a heavy chain variable domain. In some embodiments, the variable domain is a single domain antibody.

[0160] In vitro'. As used herein, the term “zzz vitro" refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc., rather than within a multi-cellular organism.

[0161] In vivo'. As used herein, the term “zzz vzvo” refers to events that occur within a multi-cellular organism, such as a human and a non-human animal. In the context of cellbased systems, the term may be used to refer to events that occur within a living cell (as opposed to, for example, in vitro systems).

[0162] Identity '. As used herein, the term “identity” refers a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules as known in the art, comparing the sequences of these molecules. The relationship determined by doing. In the art, “identity” also means the degree of sequence relatedness between nucleic acid molecules or polypeptides, and in some cases more than one nucleotide sequence or more than one. It may be determined by a match between amino acid sequence strings. “Identity” means between a gap alignment (if any) addressed by a particular mathematical model or computer program (i.e., an “algorithm”) and a smaller sequence of two or more sequences. Measure the percent identity match.Attorney Docket No. VRD-020W01

[0163] Treating'. As used herein, the term “treat,” “treatment,” or “treating” refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of and / or reduce incidence of one or more symptoms or features of a particular disease, disorder, and / or condition. Treatment may be administered to a subject who does not exhibit signs of a disease and / or exhibits only early signs of the disease for the purpose of decreasing the risk of developing pathology associated with the disease.DETAILED DESCRIPTION

[0164] The neonatal Fc receptor (FcRn) is critical to maintaining immunoglobulin G (IgG) and albumin levels through rescuing these molecules from lysosomal degradation. IgGs generally have a longer half-life than other plasma proteins due, in part, to this rescue mechanism through FcRn. However, IgGs can also play a role in the pathology of disorders such as, for example and without limitation, autoimmune disorders and inflammatory disorders. In these instances, inhibition of FcRn can be used to accelerate destruction of IgG via lysosomal degradation. Using this targeted mechanism to reduce tissue and serum concentrations of IgG has the potential to provide significant therapeutic benefit for patients with both monomeric and IC IgG autoantibody-mediated diseases.

[0165] FcRn is also critical to maintaining serum albumin levels. Low serum albumin levels, and a corresponding increase in low-density lipoprotein (LDL) levels, can increase the risk of cardiovascular disease and drug toxicity. The anti-FcRn antibodies or antigen binding fragments thereof described herein inhibit IgG binding to FcRn without significantly impacting the binding of albumin, thereby avoiding the potential harmful side effects.Anti-FcRn Antibodies

[0166] In one aspect, the present invention provides, among other things, antibodies or antigen binding fragments thereof that bind to FcRn. In some embodiments, the antibody or antigen binding fragments described herein can be adapted to various antibody formats.

[0167] The present invention provides, among other things, an antibody or antigen binding fragment that binds to neonatal Fc receptor (FcRn) with high affinity. The anti-FcRn antibodies of the present invention (1) inhibit IgG binding to FcRn with subnanomolar potency, (2) do not inhibit albumin binding and recycling, and (3) show deep and sustained IgG reduction in vivo.Attorney Docket No. VRD-020W01

[0168] A traditional antibody, also known as an immunoglobulin, is a Y-shaped structuring consisting of four polypeptides, two heavy chains and two light chains. The light chain consists of one variable region (VL) and one constant region (CL). The heavy chain consists of one variable region (VH) and at least three constant regions (CHI, CH2, CH3). The two light and two heavy chains are joined by disulfide bonds in the Y-shaped structure, with the light chains bracketing the heavy chains at the mouth of the Y-shape and continuing through the variable region. The variable regions determine the binding specificity of the antibody. Each variable region contains three hypervariable regions known as complementarity determining regions (CDRs) flanked by four relatively conserved regions known as framework regions (FRs). The three CDRs, referred to as CDR1, CDR2, and CDR3, contribute to the antibody binding specificity. Naturally occurring antibodies have often been used as starting material for engineered antibodies, such as chimeric antibodies and humanized antibodies. Examples of antibody-based antigen binding fragments include Fab, Fab’, (Fab’)2, Fv, single chain antibodies (e.g., scFv), minibodies, and diabodies. Examples of antibodies that have been modified or engineered include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies).

[0169] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a Fab, a single chain Fv (scFv), a single domain antibody (VHH), one or more CDRs, a set of three CDRs, a heavy chain variable domain (VH), a light chain variable domain (VL), a Fab-like bispecific antibodies (bsFab), a single-domain antibody-linked Fab (s-Fab), an antibody, or a combination thereof.

[0170] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a monovalent antibody. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a bivalent antibody. In some embodiments, the bivalent antibody is monospecific. In some embodiments, the bivalent antibody is bispecific.

[0171] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises an antibody derived from IgG. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises an antibody derived from IgD. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises an antibody derived from IgE. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises an antibody derived from IgA. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises an antibody derived from IgM.Attorney Docket No. VRD-020W01

[0172] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises an antibody derived from IgGl. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises an antibody derived from IgG2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises an antibody derived from IgG3. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises an antibody derived from IgG4.

[0173] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises an antigen binding fragment. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a Fab. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a single chain Fv (scFv). In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a single domain antibody (sdAb). In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VHH. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises one or more CDRs. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a set of three CDRs. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH). In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a light chain variable domain (VL). In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a Fab- like bispecific antibody. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a single-domain antibody-linked Fab (s-Fab).

[0174] In some embodiments, the FcRn binding is pH dependent. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof binds to FcRn at endosomal pH but not at physiological pH. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof binds to FcRn at pH 6.0 but not at pH 7.4.Exemplary anti-FcRn Antigen Binding Domains

[0175] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a heavy chain variable region (VH) listed in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a light chain variable region (VL) listed in Table 2. Exemplary CDRs using various numbering conventions are listed in Tables 3A, 3B, and 3C below.Attorney Docket No. VRD-020W01

[0176] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH selected from Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 60% identical to a VH in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 70% identical to a VH in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 80% identical to a VH in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 85% identical to a VH in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 90% identical to a VH in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 95% identical to a VH in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 96% identical to a VH in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 97% identical to a VH in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 98% identical to a VH in Table 1. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH at least 99% identical to a VH in Table 1.

[0177] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL selected from Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL at least 60% identical to a VL in Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL at least 70% identical to a VL in Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL at least 80% identical to a VL in Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL at least 85% identical to a VL in Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL at least 90% identical to a VL in Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL at least 95% identical to a VL in Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL at least 96% identical to a VL in Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL at least 97% identical to a VL in Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprisesAttorney Docket No. VRD-020W01 a VL at least 98% identical to a VL in Table 2. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VL at least 99% identical to a VL in Table 2.

[0178] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a heavy chain constant region (CH) comprising an amino acid sequence of SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 60% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 70% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 127. In some embodiments, the CH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 127.

[0179] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a light chain constant region (CL) comprising an amino acid sequence of SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 60% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 70% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 128. In some embodiments, the CL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 128.Attorney Docket No. VRD-020W01

[0180] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a light chain constant region (CL) comprising an amino acid sequence of SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 60% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 70% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 129. In some embodiments, the CL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 129.Table 1. Amino Acid Sequences of Exemplary Heavy Chain Variable and Constant RegionsAttorney Docket No. VRD-020W01Attorney Docket No. VRD-020W01Attorney Docket No. VRD-020W01Attorney Docket No. VRD-020W01Attorney Docket No. VRD-020W01Table 2. Amino Acid Sequences of Exemplary Light Chain Variable and Constant RegionsAttorney Docket No. VRD-020W01Attorney Docket No. VRD-020W01Attorney Docket No. VRD-020W01

[0181] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a heavy chain variable region (VH) comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to any one of SEQ ID NOs: 89-107. In some embodiments, the VH comprises an amino acid sequence according to any one of SEQ ID NOs: 89-107.

[0182] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a light chain variable region (VL) comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 1 OS- 126. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof antibody comprises a light chain variable region (VL) comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 108- 126. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 108-126. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to any one of SEQ ID NOs: 108-126. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence according to any one of SEQ ID NOs: 108-126.

[0183] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 89. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 89.

[0184] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 90. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 90.

[0185] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 91. In some embodiments, theAttorney Docket No. VRD-020W01VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 91. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 91.

[0186] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 92. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 92.

[0187] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 93. In some embodiments, theAttorney Docket No. VRD-020W01VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 93. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 93.

[0188] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 94. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 94.

[0189] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 95. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 95.

[0190] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 96. In some embodiments, theAttorney Docket No. VRD-020W01VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 96. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 96.

[0191] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 97. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 97.

[0192] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 98. In some embodiments, theAttorney Docket No. VRD-020W01VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 98. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 98.

[0193] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 99. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 99.

[0194] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 100. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 100.

[0195] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 101. In some embodiments, the VHAttorney Docket No. VRD-020W01 comprises an amino acid sequence at least 85% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 101. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 101.

[0196] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 102. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 102.

[0197] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 103. In some embodiments, the VHAttorney Docket No. VRD-020W01 comprises an amino acid sequence at least 97% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 103. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 103.

[0198] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 104. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 104.

[0199] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 105. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 105.Attorney Docket No. VRD-020W01

[0200] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 106. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 106.

[0201] In some embodiments, the VH comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 80% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 85% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 90% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 96% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 97% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 98% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence at least 99% identical to SEQ ID NO: 107. In some embodiments, the VH comprises an amino acid sequence according to SEQ ID NO: 107.

[0202] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 108. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 108. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 108.

[0203] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 109. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 109.

[0204] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 110. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 110. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 110.

[0205] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 111. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 111.

[0206] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 112. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 112.Attorney Docket No. VRD-020W01

[0207] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 113. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 113.

[0208] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 114. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 114.

[0209] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 115. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 115. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 115.

[0210] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 116. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 116.

[0211] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 117. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 117. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 117.

[0212] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 118. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 118.

[0213] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 119. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 119.Attorney Docket No. VRD-020W01

[0214] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 120. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 120.

[0215] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 121. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 121.

[0216] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 122. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 122. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 122.

[0217] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 123. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 123.

[0218] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 124. In someAttorney Docket No. VRD-020W01 embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 124. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 124.

[0219] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 125. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 125.

[0220] In some embodiments, the VL comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 80% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 85% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 90% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 96% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 97% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 98% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence at least 99% identical to SEQ ID NO: 126. In some embodiments, the VL comprises an amino acid sequence according to SEQ ID NO: 126.Attorney Docket No. VRD-020W01

[0221] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2, and a LCDR3 selected from Table 3A. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2, and a LCDR3 selected from Table 3B. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2, and a LCDR3 selected from Table 3C.Table 3A. Amino Acid Sequences of Exemplary Kabat CDRsAttorney Docket No. VRD-020W01Attorney Docket No. VRD-020W01Table 3B. Amino Acid Sequences of Exemplary Chothia CDRs.Attorney Docket No. VRD-020W01Table 3C. Amino Acid Sequences of Exemplary IMGT CDRs.Attorney Docket No. VRD-020W01Attorney Docket No. VRD-020W01

[0222] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises a VH comprising (i) a HCDR1 comprising an amino acid sequence of any one of SEQ ID NOs: 2-6, 31-39, or 60-68, (ii) a HCDR2 comprising an amino acid sequence of any one of SEQ ID NOs: 7-13, 40-44, or 69-73, and (iii) a HCDR3 comprising an amino acid sequence of any one of SEQ ID NOs: 14-17, 45-47, or 74-80. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises a VL comprising (i) a LCDR1 comprising an amino acid sequence of any one of SEQ ID NOs: 18-21, 48-50, or 81-83, (ii) a LCDR2 comprising an amino acid sequence of any one of SEQ ID NOs: 22-25 or 51-54, and (iii) a LCDR3 comprising an amino acid sequence of any one of SEQ ID NOs: 26-30, 55-59, or 84-88.

[0223] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 according to the consensus sequence of GX2YX4H, wherein X2 comprises Y or F and X4 comprises M or I; (ii) a HCDR2 according to the consensus sequence of WINPX5SGX8TNYAQX14FQX17, wherein X5 comprises K or N, X8 comprises D, G, or H, X14 comprises K or R, and X17 comprises G or D; and (iii) a HCDR3 according to the consensus sequence of SGIAX5NWFDP, wherein X5 comprises F or Y. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 according to the consensus sequence of GGNNIGSKX9VH, wherein X9 comprises N or S; (ii) a LCDR2 according to the consensus sequence of X1DSX4RPS, wherein Xi comprises Y, F, or R, and X4 comprises N or D; and (iii) a LCDR3 according to the consensus sequence of QVWDSXeSDHXioV, wherein Xe comprises S or G, and X10 comprises Y, W, or V.

[0224] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising SEQ ID NO: 5; (ii) a HCDR2 comprising SEQ ID NO: 10; and (iii) a HCDR3 according to the consensus sequence of XiGDNWNHYYYYYMDV, wherein Xi comprises G or E. In some embodiments, the anti-FcRn antibody or antigen binding domain comprises (i) a LCRD1 according to the consensus sequence ofAttorney Docket No. VRD-020W01XiASQSISSWLA, wherein Xi comprises Q or R; (ii) a LCDR2 comprising SEQ ID NO: 25; and (iii) a LCDR3 comprising SEQ ID NO: 30.

[0225] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 2, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 14. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 2, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 14. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 2, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 14. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 26.

[0226] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 2, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 14. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 23, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 2, (ii) a HCDR2 that differs by noAttorney Docket No. VRD-020W01 more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 14. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 23, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO:2, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 14. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 23, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 27.

[0227] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 8, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 19, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 24, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 8, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 19, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 24, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO:3, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 8, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 19, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 24, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 26.

[0228] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 9, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 28. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 9, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 28. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 4, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 9, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 28.

[0229] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 2, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 14. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 2, (ii) a HCDR2 that differs by noAttorney Docket No. VRD-020W01 more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 14. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO:2, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 14. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 27.

[0230] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 8, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 8, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO:3, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 8, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 27.

[0231] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 8, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 8, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 8, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 26.

[0232] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 9, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 that differs by noAttorney Docket No. VRD-020W01 more than 2 amino acids from SEQ ID NO: 9, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 4, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 9, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 27.

[0233] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 27.

[0234] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 9, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 29. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 9, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 29. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 4, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 9, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 29.

[0235] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 7, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 that differs by noAttorney Docket No. VRD-020W01 more than 2 amino acids from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 4, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 7, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 26.

[0236] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 4, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 8, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 4, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 8, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 27. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 4, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 8, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 27.

[0237] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 5, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 10, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 16. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 20, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 25, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 30. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 5, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 10, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 16. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 20, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 25, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 30. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 5, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 10, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 16. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 20, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 25, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 30.

[0238] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 5, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 10, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 16. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 21, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 25, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 30. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 5, (ii) a HCDR2 that differs by noAttorney Docket No. VRD-020W01 more than 2 amino acids from SEQ ID NO: 10, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 16. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 21, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 25, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 30. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 5, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 10, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 16. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 21, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 25, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 30.

[0239] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 11, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 11, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 11, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 26.

[0240] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 5, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 10, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 17. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 20, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 25, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 30. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 5, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 10, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 17. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 20, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 25, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 30. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 5, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 10, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 17. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 20, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 25, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 30.

[0241] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 12, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 that differs by noAttorney Docket No. VRD-020W01 more than 2 amino acids from SEQ ID NO: 12, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 12, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 26.

[0242] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 6, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 13, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 18, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 22, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 6, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 13, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 18, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 6, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 13, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 18, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 22, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 26.

[0243] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 3, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 9, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 19, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 24, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 9, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 19, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 24, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 26. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 3, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 9, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 15. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 19, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 24, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 26.

[0244] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 31, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 45. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 31, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 45. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 31, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 45. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 55.

[0245] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 31, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 45. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 52, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 31, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 45. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 52, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 31, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 45. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 52, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 56.

[0246] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 32, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 49, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 53, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 32, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 49, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 53, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 32, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 49, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 53, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 55.

[0247] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 33, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 57. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 33, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 57. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 33, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 57.

[0248] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 31, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 45. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 31, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 45. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 31, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 45. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 56.

[0249] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 33, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 33, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 33, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 56.

[0250] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 32, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 32, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 32, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 55.

[0251] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 34, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 34, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 34, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 56.

[0252] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 35, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 35, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 35, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 56.

[0253] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 34, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 34, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 58. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 34, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 58.

[0254] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 36, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 40, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 36, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 36, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 40, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 55.

[0255] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 37, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 37, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 56. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 37, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 56.

[0256] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 38, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 43, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 47. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 50, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 54, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 38, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 43, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 47. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 50, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 54, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 59. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 38, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 43, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 47. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 50, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 54, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 59.

[0257] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 35, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 35, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 35, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 55.

[0258] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 38, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 43, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 47. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 50, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 54, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 38, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 43, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 47. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 50, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 54, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 59. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 38, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 43, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 47. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 50, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 54, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 59.

[0259] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 33, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 41, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 33, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 33, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 41, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 55.

[0260] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 39, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 44, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 48, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 39, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 44, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 48, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 39, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 44, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 48, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 55.

[0261] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 32, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 42, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 49, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 53, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 32, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 46. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 49, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 53, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 55. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 32, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 42, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 46. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 49, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 53, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 55.

[0262] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 60, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 74. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 84. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 60, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 74. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 84. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 60, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 74. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 84.

[0263] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 60, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 74. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 52, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 60, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 74. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 52, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 60, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 74. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 52, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 85.

[0264] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 61, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 70, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 82, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 53, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 84. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 61, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 70, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 82, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 53, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 84. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 61, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 70, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 82, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 53, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 84.

[0265] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 62, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 71, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 86. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 62, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 71, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 86. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 62, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 71, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 86.

[0266] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 60, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 74. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 60, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 74. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 60, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 74. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 85.

[0267] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 62, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 70, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 62, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 70, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 62, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 70, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 85.

[0268] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 61, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 70, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 84. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 61, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 70, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 84. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 61, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 70, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 84.

[0269] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 63, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 71, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 76. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 63, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 71, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 76. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 63, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 71, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 76. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 85.

[0270] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 64, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 77. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 64, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 77. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 64, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 77. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 85.

[0271] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 63, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 71, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 76. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 87. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 63, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acids from SEQ ID NO: 71, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 76. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 87. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 63, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 71, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 76. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 87.

[0272] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 65, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 69, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 84. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 65, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 75. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 84. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 65, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 69, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 75. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 thatAttorney Docket No. VRD-020W01 differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 84.

[0273] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 66, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 70, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 78. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 81, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 51, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 66, (ii) a HCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 70, and (iii) a HCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 78. In some embodiments, the anti- FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 2 amino acids from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 2 amino acids from SEQ ID NO: 85. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 66, (ii) a HCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 70, and (iii) a HCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 78. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 that differs by no more than 1 amino acid from SEQ ID NO: 81, (ii) a LCDR2 that differs by no more than 1 amino acid from SEQ ID NO: 51, and (iii) a LCDR3 that differs by no more than 1 amino acid from SEQ ID NO: 85.

[0274] In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 comprising an amino acid sequence of SEQ ID NO: 67, (ii) a HCDR2 comprising an amino acid sequence of SEQ ID NO: 72, and (iii) a HCDR3 comprising an amino acid sequence of SEQ ID NO: 79. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 83, (ii) a LCDR2 comprising an amino acid sequence of SEQ ID NO: 54, and (iii) a LCDR3 comprising an amino acid sequence of SEQ ID NO: 88. In some embodiments, the anti-FcRn antibody or antigen binding fragment thereof comprises (i) a HCDR1 that differs by no more than 2 amino acids from SEQ ID NO: 67, (ii) a HCDR2Attorney Docket No. VRD-020W01 that differs by no more than 2 amino acid...

Claims

Attorney Docket No. VRD-020W01CLAIMSWhat is claimed is:

1. An antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn) comprising a. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 2, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 14, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26; b. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 2, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 14, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 23, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27; c. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 8, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 19, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQAttorney Docket No. VRD-020W01ID NO: 24, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26; d. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 9, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 28; e. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 2, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 14, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27; f. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 8, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27;Attorney Docket No. VRD-020W01 g. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 8, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26; h. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 9, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27; i. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27; j . a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids fromAttorney Docket No. VRD-020W01SEQ ID NO: 9, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 29; k. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 7, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26; l. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 4, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 8, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 27; m. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 5, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 10, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 16, a LCDR1 comprising an amino acid sequence that is identical to or differs by noAttorney Docket No. VRD-020W01 more than 2 amino acids from SEQ ID NO: 20, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 25, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 30; n. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 5, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 10, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 16, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 21, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 25, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 30; o. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 11, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26; p. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 5, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 10, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 17, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 20, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids fromAttorney Docket No. VRD-020W01SEQ ID NO: 25, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 30; q. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 12, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26; r. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 6, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 13, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 18, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 22, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26; or s. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 3, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 9, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 15, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 19, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 24, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 26.Attorney Docket No. VRD-020W012. An antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn) comprising a. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 31, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 45, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55; b. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 31, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 45, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 52, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56; c. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 32, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 41, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 49, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 53, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55;Attorney Docket No. VRD-020W01 d. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 33, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 57; e. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 31, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 45, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56; f. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 33, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 41, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56; g. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 32, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids fromAttorney Docket No. VRD-020W01SEQ ID NO: 41, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55; h. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 34, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56; i. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 35, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56; j . a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 34, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by noAttorney Docket No. VRD-020W01 more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 58; k. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 36, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 40, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55; l. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 37, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 41, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 56; m. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 38, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 43, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 47, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 50, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids fromAttorney Docket No. VRD-020W01SEQ ID NO: 54, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 59; n. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 35, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55; o. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 38, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 43, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 47, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 50, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 54, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 59; p. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 33, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 41, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55;Attorney Docket No. VRD-020W01 q. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 39, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 44, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 48, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55; or r. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 32, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 42, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 46, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 49, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 53, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 55.

3. An antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn) comprising a. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 60, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 69, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 74, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84;Attorney Docket No. VRD-020W01 b. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 60, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 69, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 74, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 52, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85; c. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 61, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 82, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 53, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84; d. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 62, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 71, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 86; e. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 60, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids fromAttorney Docket No. VRD-020W01SEQ ID NO: 69, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 74, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85; f. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 62, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85; g. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 61, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84; h. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 63, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 71, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 76, a LCDR1 comprising an amino acid sequence that is identical to or differs by noAttorney Docket No. VRD-020W01 more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85; i. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 64, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 69, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 77, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85; j . a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 63, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 71, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 76, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 87; k. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 65, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 69, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids fromAttorney Docket No. VRD-020W01SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84; l. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 66, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 78, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 85; m. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 67, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 72, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 79, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 83, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 54, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 88; n. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 64, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 71, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 77, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84;Attorney Docket No. VRD-020W01 o. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 67, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 72, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 80, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 83, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 54, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 88; p. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 62, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 70, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 77, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84; q. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 68, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 73, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 81, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 51, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84; or r. a HCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 61, a HCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids fromAttorney Docket No. VRD-020W01SEQ ID NO: 71, and a HCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 75, a LCDR1 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 82, a LCDR2 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 53, and a LCDR3 comprising an amino acid sequence that is identical to or differs by no more than 2 amino acids from SEQ ID NO: 84.

4. The antibody or antigen binding fragment thereof of claim 1, wherein the antibody or antigen binding fragment thereof comprises a. a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 7, a HCDR3 of SEQ ID NO: 14, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26; b. a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 7, a HCDR3 of SEQ ID NO: 14, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 23, and a LCDR3 of SEQ ID NO: 27; c. a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 8, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 19, a LCDR2 of SEQ ID NO: 24, and a LCDR3 of SEQ ID NO: 26; d. a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 28; e. a HCDR1 of SEQ ID NO: 2, a HCDR2 of SEQ ID NO: 7 a HCDR3 of SEQ ID NO: 14, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27; f. a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 8, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27; g. a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 8, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26;Attorney Docket No. VRD-020W01 h. a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27; i. a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 7, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27; j . a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 29; k. a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 7, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26; l. a HCDR1 of SEQ ID NO: 4, a HCDR2 of SEQ ID NO: 8, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 27; m. a HCDR1 of SEQ ID NO: 5, a HCDR2 of SEQ ID NO: 10, a HCDR3 of SEQ ID NO: 16, a LCDR1 of SEQ ID NO: 20, a LCDR2 of SEQ ID NO: 25, and a LCDR3 of SEQ ID NO: 30; n. a HCDR1 of SEQ ID NO: 5, a HCDR2 of SEQ ID NO: 10, a HCDR3 of SEQ ID NO: 16, a LCDR1 of SEQ ID NO: 21, a LCDR2 of SEQ ID NO: 25, and a LCDR3 of SEQ ID NO: 30; o. a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 11, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26; p. a HCDR1 of SEQ ID NO: 5, a HCDR2 of SEQ ID NO: 10, a HCDR3 of SEQ ID NO: 17, a LCDR1 of SEQ ID NO: 20, a LCDR2 of SEQ ID NO: 25, and a LCDR3 of SEQ ID NO: 30; q. a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 12, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26; r. a HCDR1 of SEQ ID NO: 6, a HCDR2 of SEQ ID NO: 13, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 18, a LCDR2 of SEQ ID NO: 22, and a LCDR3 of SEQ ID NO: 26; orAttorney Docket No. VRD-020W01 s. a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 19, a LCDR2 of SEQ ID NO: 24, and a LCDR3 of SEQ ID NO: 26.

5. The antibody or antigen binding fragment thereof of claim 2, wherein the antibody or antigen binding fragment thereof comprises a. a HCDR1 of SEQ ID NO: 31, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 45, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55; b. a HCDR1 of SEQ ID NO: 31, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 45, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 52, and a LCDR3 of SEQ ID NO: 56; c. a HCDR1 of SEQ ID NO: 32, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 49, a LCDR2 of SEQ ID NO: 53, and a LCDR3 of SEQ ID NO: 55; d. a HCDR1 of SEQ ID NO: 33, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48 a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 57; e. a HCDR1 of SEQ ID NO: 31, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 45, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56; f. a HCDR1 of SEQ ID NO: 33, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56; g. a HCDR1 of SEQ ID NO: 32, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55; h. a HCDR1 of SEQ ID NO: 34, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56; i. a HCDR1 of SEQ ID NO: 35, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56;Attorney Docket No. VRD-020W01 j . a HCDR1 of SEQ ID NO: 34, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 58; k. a HCDR1 of SEQ ID NO: 36, a HCDR2 of SEQ ID NO: 40, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55; l. a HCDR1 of SEQ ID NO: 37, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 56; m. a HCDR1 of SEQ ID NO: 38, a HCDR2 of SEQ ID NO: 43, a HCDR3 of SEQ ID NO: 47, a LCDR1 of SEQ ID NO: 50, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 59; n. a HCDR1 of SEQ ID NO: 35, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55; o. a HCDR1 of SEQ ID NO: 38, a HCDR2 of SEQ ID NO: 43, a HCDR3 of SEQ ID NO: 47, a LCDR1 of SEQ ID NO: 50, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 59; p. a HCDR1 of SEQ ID NO: 33, a HCDR2 of SEQ ID NO: 41, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55; q. a HCDR1 of SEQ ID NO: 39, a HCDR2 of SEQ ID NO: 44, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 48, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 55; or r. a HCDR1 of SEQ ID NO: 32, a HCDR2 of SEQ ID NO: 42, a HCDR3 of SEQ ID NO: 46, a LCDR1 of SEQ ID NO: 49, a LCDR2 of SEQ ID NO: 53, and a LCDR3 of SEQ ID NO: 55.

6. The antibody or antigen binding fragment thereof of claim 3, wherein the antibody or antigen binding fragment thereof comprises a. a HCDR1 of SEQ ID NO: 60, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 74, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84;Attorney Docket No. VRD-020W01 b. a HCDR1 of SEQ ID NO: 60, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 74, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 52, and a LCDR3 of SEQ ID NO: 85; c. a HCDR1 of SEQ ID NO: 61, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 82, a LCDR2 of SEQ ID NO: 53, and a LCDR3 of SEQ ID NO: 84; d. a HCDR1 of SEQ ID NO: 62, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 86; e. a HCDR1 of SEQ ID NO: 60, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 74, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85; f. a HCDR1 of SEQ ID NO: 62, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85; g. a HCDR1 of SEQ ID NO: 61, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84; h. a HCDR1 of SEQ ID NO: 63, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 76, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85; i. a HCDR1 of SEQ ID NO: 64, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 77, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85; j . a HCDR1 of SEQ ID NO: 63, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 76, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 87; k. a HCDR1 of SEQ ID NO: 65, a HCDR2 of SEQ ID NO: 69, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84; l. a HCDR1 of SEQ ID NO: 66, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 78, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 85;Attorney Docket No. VRD-020W01 m. a HCDR1 of SEQ ID NO: 67, a HCDR2 of SEQ ID NO: 72, a HCDR3 of SEQ ID NO: 79, a LCDR1 of SEQ ID NO: 83, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 88; n. a HCDR1 of SEQ ID NO: 64, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 77, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84; o. a HCDR1 of SEQ ID NO: 67, a HCDR2 of SEQ ID NO: 72, a HCDR3 of SEQ ID NO: 80, a LCDR1 of SEQ ID NO: 83, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 88; p. a HCDR1 of SEQ ID NO: 62, a HCDR2 of SEQ ID NO: 70, a HCDR3 of SEQ ID NO: 77, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84; q. a HCDR1 of SEQ ID NO: 68, a HCDR2 of SEQ ID NO: 73, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 81, a LCDR2 of SEQ ID NO: 51, and a LCDR3 of SEQ ID NO: 84; or r. a HCDR1 of SEQ ID NO: 61, a HCDR2 of SEQ ID NO: 71, a HCDR3 of SEQ ID NO: 75, a LCDR1 of SEQ ID NO: 82, a LCDR2 of SEQ ID NO: 53, and a LCDR3 of SEQ ID NO: 84.

7. The antibody or antigen binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region (VH) comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 89-107.

8. The antibody or antigen binding fragment thereof of claim 7, wherein the VH comprises an amino acid sequence identical to any one of SEQ ID NOs: 89-107.

9. The antibody or antigen binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen binding fragment thereof comprises a light chain variable region (VL) comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 108-126.Attorney Docket No. VRD-020W0110. The antibody or antigen binding fragment thereof of claim 9, wherein the VL comprises an amino acid sequence identical to any one of SEQ ID NOs: 108-126.

11. The antibody or antigen binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen binding fragment thereof comprises a Fab, a single chain Fv (scFv), a single domain antibody (VHH), one or more CDRs, a variable heavy chain (VH), a variable light chain (VL), a Fab-like bispecific antibody (bsFab), a single-domain antibody-linked Fab (s-Fab), an antibody, or a combination thereof.

12. The antibody or antigen binding fragment thereof of any one of the preceding claims, further comprising an Fc region.

13. The antibody or antigen binding fragment thereof of claim 12, wherein the Fc region is derived from an IgGl Fc region, an IgG2 Fc region, an IgG3 Fc region, or an IgG4 Fc region.

14. The antibody or antigen binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen binding fragment thereof comprises a heavy chain constant region (CH) comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 127.

15. The antibody or antigen binding fragment thereof of claim 14, wherein the CH comprises an amino acid sequence identical to SEQ ID NO: 127.

16. The antibody or antigen binding fragment thereof of any one of claims 12-15, wherein the Fc region comprises one or more modifications.

17. The antibody or antigen binding fragment thereof of any one of claims 12-16, wherein the Fc region further comprises knob-in-to-hole mutations.

18. The antibody or antigen binding fragment thereof of any one of claims 12-17, wherein the Fc region comprises one or more amino acid substitutions selected from M252Y, S254T, T256E, M428L, H433K, N434Y, or N434F, numbered according to the EU index.

19. The antibody or antigen binding fragment thereof of claim 18, wherein the Fc region comprises amino acid substitutionsAttorney Docket No. VRD-020W01 a. M252Y, S254T, T256E, H433K, and N434F; b. M252Y, S254T, T256E, M428L, H433K, and N434F; or c. M252Y, S254T, T256E, H433K, and N434Y, numbered according to the EU index.

20. The antibody or antigen binding fragment thereof of any one of claims 12-15, wherein the Fc region is not modified.

21. The antibody or antigen binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen binding fragment thereof comprises a light chain constant region (CL) comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 128 or 129.

22. The antibody or antigen binding fragment thereof of claim 21, wherein the CL comprises an amino acid sequence identical to SEQ ID NO: 128 or 129.

23. The antibody or antigen binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen binding fragment thereof is monovalent.

24. The antibody or antigen binding fragment thereof of any one of claims 1-22, wherein the antibody or antigen binding fragment thereof is bivalent.

25. The antibody or antigen binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'8M, IxlO'9M, IxlO'10M, IxlO'11M, or IxlO'12M at pH 6.0 as measured by surface plasmon resonance (SPR).

26. The antibody or antigen binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen binding fragment thereof binds FcRn with a KD less than or equal to IxlO'8M, IxlO'9M, IxlO'10M, IxlO'11M, or IxlO'12M at pH 7.4 as measured by SPR.

27. The antibody or antigen binding fragment thereof of claim 25 or 26, wherein the ratio of the KD at pH 7.4 to the KD at pH 6.0, as measured by SPR, is less than 10, 9, 8, 7, 6, 5, 4, 3, 2.5, 2, 1.5, or 1.Attorney Docket No. VRD-020W0128. The antibody or antigen binding fragment thereof of any of the preceding claims, wherein the antibody or antigen binding fragment thereof blocks IgG from binding to FcRn.

29. The antibody or antigen binding thereof of any of the preceding claims, wherein the antibody or antigen binding fragment thereof blocks or reduces naturally occurring recycling of IgGs.

30. The antibody or antigen binding fragment thereof of claim 29, wherein the antibody or antigen binding fragment thereof results in increased catabolism of the IgGs.

31. The antibody or antigen binding fragment thereof of claim 29 or 30, wherein the IgGs comprise pathogenic autoantibodies.

32. An antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn) comprising a HCDR1 of SEQ ID NO: 3, a HCDR2 of SEQ ID NO: 9, a HCDR3 of SEQ ID NO: 15, a LCDR1 of SEQ ID NO: 19, a LCDR2 of SEQ ID NO: 24, and a LCDR3 of SEQ ID NO: 26.

33. An antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn) comprising a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 107 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 126.

34. An antibody or antigen binding fragment thereof that binds to neonatal Fc receptor (FcRn) comprising a. a heavy chain comprising a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 107 and a heavy chain constant region (CH) comprising an amino acid sequence of SEQ ID NO: 127; and b. a light chain comprising a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 126 and a light chain constant region (CL) comprising an amino acid sequence of SEQ ID NO: 128.

35. A nucleic acid encoding the antibody or antigen binding fragment thereof of any one of the preceding claims.

36. A vector comprising the nucleic acid of claim 35.Attorney Docket No. VRD-020W0137. A host cell comprising the nucleic acid of claim 35 or the vector of claim 36.

38. A pharmaceutical composition comprising the antibody or antigen binding fragment thereof of any one of claims 1-34, the nucleic acid of claim 35, the vector of claim 36, or the host cell of claim 37, and a pharmaceutically acceptable carrier.

39. A method of treating or preventing a disease or disorder in a patient in need thereof, the method comprising administering to the patient an effective amount of the antibody or antigen binding fragment thereof of any one of claims 1-34, or the pharmaceutical composition of claim 38.

40. The method of claim 39, wherein the disease or disorder is an autoimmune disease.

41. The method of claim 39 or 40, wherein the disease or disorder is generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy, myositis, autoimmune encephalitis, myelin oligodendrocyte glycoprotein antibody disorders (MOG-antibody disorder), membranous nephropathy, lupus nephritis, thyroid eye disease, warm autoimmune hemolytic anemia, hemolytic disease of the fetus and newborn, idiopathic thrombocytopenic purpura, primary Sjogren’s Syndrome, systemic lupus erythematosus, rheumatoid arthritis, bullous pemphigoid, pemphigus foliaceus, pemphigus vulgaris, or cutaneous lupus erythematosus.

42. A method for treating a pathology associated with elevated levels of an IgG in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the antibody or antigen binding fragment thereof of any one of claims 1-34, or the pharmaceutical composition of claim 38.

43. A method of reducing biological activity of an IgG in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the antibody or antigen binding fragment thereof of any one of claims 1-34, or the pharmaceutical composition of claim 38.

44. The method of claim 42 or 43, wherein administration of the antibody or antigen binding fragment thereof reduces IgG levels in the patient to less than 60%, to less than 50%, to less than 40%, to less than 35%, or to less than 30% relative to a baseline for at least 5Attorney Docket No. VRD-020W01 days, at least 7 days, at least 10 days, at least 15 days, or at least 20 days postadministration.

45. The method of claim 44, wherein the baseline is the IgG level in the patient prior to administration of the antibody or antigen binding fragment thereof or the IgG level in a comparable patient without the administration of the antibody or antigen binding fragment thereof.

Images